Canada - English - Health Canada

natco pharma (canada) inc - pomalidomide - capsule - 2mg - pomalidomide 2mg

Canada - English - Health Canada

apotex inc - pomalidomide - capsule - 2mg - pomalidomide 2mg

Canada - English - Health Canada

dr reddy's laboratories ltd - pomalidomide - capsule - 2mg - pomalidomide 2mg

Australia - English - Department of Health (Therapeutic Goods Administration)

celgene pty ltd - pomalidomide, quantity: 2 mg - capsule - excipient ingredients: mannitol; pregelatinised maize starch; gelatin; titanium dioxide; iron oxide yellow; indigo carmine; erythrosine; iron oxide black; shellac; propylene glycol; strong ammonia solution; ethanol absolute; purified water; butan-1-ol; isopropyl alcohol; sodium stearylfumarate - pomalyst, in combination with bortezomib and dexamethasone, is indicated for the treatment of patients with relapsed or refractory multiple myeloma who have received at least one prior treatment regimen including lenalidomide. pomalyst, in combination with dexamethasone, is indicated for the treatment of patients with relapsed and refractory multiple myeloma who have received at least two prior treatment regimens, including both lenalidomide and bortezomib, and have demonstrated disease progression on the last therapy.

Canada - English - Health Canada

natco pharma (canada) inc - pomalidomide - capsule - 2mg - pomalidomide 2mg

New Zealand - English - Medsafe (Medicines Safety Authority)

celgene limited - pomalidomide 2mg;   - capsule - 2 mg - active: pomalidomide 2mg   excipient: erythrosine gelatin indigo carmine iron oxide yellow mannitol pregelatinised maize starch sodium stearyl fumarate titanium dioxide - pomalidomide, in combination with dexamethasone, is indicated for the treatment of patients with relapsed and refractory multiple myeloma who have received at least two prior treatment regimens, including both lenalidomide and bortezomib, and have demonstrated disease progression on the last therapy

Australia - English - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - pomalidomide, quantity: 2 mg - capsule, hard - excipient ingredients: croscarmellose sodium; mannitol; sodium stearylfumarate; pregelatinised starch; titanium dioxide; indigo carmine; purified water; iron oxide yellow; erythrosine; gelatin; propylene glycol; butan-1-ol; isopropyl alcohol; shellac; ethanol absolute; ammonia; potassium hydroxide - pomalidomide, in combination with bortezomib and dexamethasone, is indicated for the treatment of patients with relapsed or refractory multiple myeloma who have received at least one prior treatment regimen including lenalidomide.,pomalidomide, in combination with dexamethasone, is indicated for the treatment of patients with relapsed and refractory multiple myeloma who have received at least two prior treatment regimens, including both lenalidomide and bortezomib, and have demonstrated disease progression on the last therapy.

Canada - English - Health Canada

natco pharma (canada) inc - pomalidomide - capsule - 1mg - pomalidomide 1mg

Canada - English - Health Canada

natco pharma (canada) inc - pomalidomide - capsule - 3mg - pomalidomide 3mg

Canada - English - Health Canada

natco pharma (canada) inc - pomalidomide - capsule - 4mg - pomalidomide 4mg